There’s a good chance some of the most expensive drugs out there may soon get a bit cheaper.
Under provisions in the Affordable Care Act, it’s now easier to get approval for what are called biosimilar drugs. These are drugs that are similar – get it – to biologic, or biologically derived, medications.
Earlier this week, a panel unanimously recommended that the FDA approve the first biosimilar in the U.S. If these copycat drugs pick up steam, Rand predicts savings could reach billions in short order.
News and information you need, from a source you trust.
In a world where it’s easier to find disinformation than real information, trustworthy journalism is critical to our democracy and our everyday lives. And you rely on Marketplace to be that objective, credible source, each and every day.
This vital work isn’t possible without you. Marketplace is sustained by our community of Investors—listeners, readers, and donors like you who believe that a free press is essential – and worth supporting.